The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents

Cancer Epidemiology

Volumn 33, Issue 3-4, 2009, Pages 293-299

  Sun, Buxiang ^a   Wakame, Koji ^a   Sato, Eri ^a   Nishioka, Hiroshi ^a   Aruoma, Okezie I ^b   Fujii, Hajime ^a  

^a Amino Up Chemical Co   (Japan)

^b TOURO COLLEGE   (United States)

Author keywords

6 Mercaptopurine; Active hexose correlated compound (AHCC); Alopecia (hair loss); Anticancer drugs; Cancer chemotherapy side effects; Complementary medicine; Cytosine arabinoside; Drug induced liver injury; Economics of cancer therapy; Methotrexate

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ALANINE AMINOTRANSFERASE; AMINO ACID DERIVATIVE; ASPARTATE AMINOTRANSFERASE; CYTARABINE; HEXOSE; LIPID; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; MINERAL; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FEMALE; HAIR FOLLICLE; HAIR GROWTH; HAIR LOSS; LENTINUS EDODES; LEUKOCYTE COUNT; LIVER HYPERTROPHY; LIVER INJURY; MALE; MOUSE; MYCELIUM; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; REGULATORY MECHANISM; SINGLE DRUG DOSE; SUPPLEMENTATION; TISSUE DEGENERATION;

6-MERCAPTOPURINE; ALOPECIA; ANIMALS; ANIMALS, NEWBORN; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WEIGHT; CYTARABINE; FEMALE; HAIR FOLLICLE; MALE; METHOTREXATE; MICE; POLYSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY; SHIITAKE MUSHROOMS;

EID: 70349952445     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.07.006     Document Type: Article

References (74)

1. Viale P.H. Chemotherapy and cutaneous toxicities: implications for oncology nurses. Semin Oncol Nurs 22 (2006) 144-151
2. Symonds R.P., and Foweraker K. Principles of chemotherapy and radiotherapy. Curr Obstet Gynaecol 16 (2006) 100-106
3. Tappenden P., Chilcott J., Ward S., Eggington S., Hind D., and Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 42 (2006) 2867-2875
4. Niezen M.G.H., Stolk E.A., Steenhoek A., and Uyl-De Groot C.A. Inequalities in oncology care: economic consequences of high cost drugs. Eur J Cancer 42 (2006) 2887-2892
5. Lista P., Porcu P., Avanzi G.C., and Pegoraro L. Interleukin-3 enhances the cytotoxic activity of 1-beta-d-arabinofuranosylcytosine (Ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol 70 (1988) 121
6. Cannistra S.A., Groshek P., and Griffin J.D. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3 (1989) 328-334
7. Jacobs P. Myelodysplasia and the leukemias. Disease-a-Month 43 (1997) 639-644
8. Grant S., and Ara-C. cellular and molecular pharmacology. Adv Cancer Res 72 (1988) 197-233
9. Parisi E., Draznin J., Stoopler E., Schuster S.J., Porter D., and Sollecito T.P. Acute myelogenous leukemia: advances and limitations of Treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002) 257-263
10. Lengfelder E., Saussele S., Weisser A., Buchner T., and Hehlmanna R. Treatment concepts of acute promyelocytic leukaemia. Crit Rev Oncol/Hematol 56 (2005) 261-274
11. Gilhar A., Landau M., Assy B., Shalaginov R., Serafimovich S., and Kalis R.S. Melanocyte associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc (scid) mice. J Invest Dermatol 117 (2001) 1357-1362
12. Han A., and Mirmirani P. Clinical approach to the patient with alopecia. Semin Cutan Med Surg 25 (2006) 11-23
13. Wade M.S., and Sinclair R.D. Disorders of hair in infants and children other than alopecia. Clinic Dermatol 20 (2002) 16-28
14. Lutz M.E., and Pittelkow M.R. Progressive generalized alopecia due to systemic amyloidosis. J Am Acad Dermatol 46 (2002) 434-436
15. D'Agostini F., Balansky R., Pesce C., Fiallo P., Lubet R.A., Kelloff G.J., and De Flora S. Induction of alopecia in mice exposed to cigarette smoke. Toxicol Lett 114 (2000) 117-123
16. D'Agostini F., Bagnasco M., Giunciuglio D., Albini A., and De Flora S. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol 13 (1998) 217-224
17. D'Agostini F., Fiallo P., Pennisi T.M., and De Flora S. Chemoprevention of smoke-induced alopecia in mice by oral administration of l-cystine and vitamin B6. J Dermatol Sci 46 (2007) 189-198
18. Smith G.B., and Fenske N.A. Cutaneous manifestations and consequences of smoking. J Am Acad Dermatol 34 (1996) 717-732
19. Hersh E.M., Wong V.G., Henderson E.S., and Freirich E.J. Hepatotoxic effects of methotrexate. Cancer 19 (1966) 600-606
20. Dervieux T., Hancock M.L., Pui C.-H., Rivera G.K., Sandlund J.T., Boyett J., et al. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 73 (2003) 506-516
21. Kamen B.A., Nylen P.A., Camitta B.M., and Bertino J.R. Methotrexate accumulation and folate depletion in cell as a possible mechanism of chronic toxicity to the drug. Br J Haematol 49 (1981) 355-360
22. Pui C.H., and Evans W.E. Acute lymphoblastic leukaemia. N Engl J Med 339 (1998) 605-615
23. Kremer J.M., Galivan J., Streckfuss A., and Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 29 (1986) 832-835
24. Kugathasan S., Newman A.J., Dahms B.B., and Boyle J.T. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr 128 (1996) 149-151
25. Innocenti F., and Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 38 (2002) 639-644
26. McLeod H.L., Coulthard S., Thomas A.E., Pritchard S.C., King D.J., Richards S.M., Eden O.B., Hall A.G., and Gibson B.E. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 105 (1999) 696-700
27. Relling M.V., Hancock M.L., Boyett J.M., Pui C.H., and Evans W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 (1999) 2817-2823
28. Cetiner M., Sener G., Sehirli A.O., Eksioglu-Demiralp E., Ercan F., Sirvanci S., et al. Taurine protects against methotrexate-induced toxicityand inhibits leukocyte death. Toxicol Appl Pharmacol 209 (2005) 39-50
29. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 (1992) 329-339
30. Waters T.R., and Swann P.F. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 36 (1997) 2501-2506
31. Bökkerink J.P., Stet E.H., De Abreu R.A., Damen F.J., Hulscher T.W., Bakker M.A., et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 45 (1993) 1455-1463
32. Onderdonk A.B., Cisneros R.L., Hinkson P., and Ostroff G. Anti-infective effect of poly-β1-6-glucotriosyl-β1-3-glucopyranose glucan in vivo. Infect Immun 60 (1992) 1642-1647
33. Nakagawa Y., Ohno N., and Murai T. Suppression by Candida albicans β-glucan of cytokine release from activated human monocytes and from T-cells in the presence of monocytes. J Infect Dis 187 (2003) 710-713
34. Wei D., Williams D., and Browder W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int Immunopharmacol 2 (2002) 1163-1172
35. Matsui Y., Uhara J., Satoi S., Kaibori M., Yamada H., Kitade H., et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 37 (2002) 78-86
36. Cleary J.A., Kelly G.E., and Husband A.J. The effect of molecular weight and β-1,6-linkages on priming of macrophage function in mice by (1,3)-β-d-glucan. Immunol Cell Biol 77 (1999) 395-403
37. Engstad C.S., Engstad R.E., Olsen J.O., and Osterud B. The effect of soluble β-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int Immunopharmacol 2 (2002) 1585-1597
38. Ljungman A.G., Leanderson P., and Tagesson C. (1-3)-β-d-glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ Toxicol Pharmacol 5 (1998) 273-281
39. Hashimoto T., Ohno N., Adachi Y., and Yadomae T. Enhanced production of inducible nitric oxide synthase by β-glucans in mice. FEMS Immunol Med Microbiol 19 (1997) 131-135
40. Şener G., Ekşioǧlu-Demiralp E., Çetiner M., Ercan F., and Yeǧen B.C. Beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur J Pharmacol 542 (2006) 170-178
41. Wakame K. Protective effects of active hexose correlated compound (AHCC) on the onset of diabetes induced by streptozotocin in the rat. Biomed Res 20 (1999) 145-152
42. Ghoneum M., Wimbley M., Salem F., Mcklain A., Attallah N., and Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). Int J Immunother 11 (1995) 23-28
43. Gao Y., Zhang D., Sun B., Fujii H., Kosuna K.-I., and Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother 55 (2006) 1258-1266
44. Matsushita K., Kuramitsu Y., Ohiro Y., Obara M., Kobayashi M., Li Y.Q., et al. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anti-Cancer Drugs 9 (1998) 343-350
45. Cowawintaweewat S., Manoromana S., Sriplung H., Khuhaprema T., Tongtawe P., Tapchaisri P., et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol 24 (2006) 33-45
46. Kidd P.M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5 (2000) 4-27
47. Hirose A., Sato E., Fujii H., Sun B., Nishioka H., and Aruoma O.I. The influence of active hexose correlated compounds (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 222 (2007) 152-158
48. Aviles H., Belay T., Fountain K., Vance M., Sun B., and Sonnenfeld G. Active hexose correlated compound enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol 95 (2003) 491-496
49. Omura T., Sato R., Coopen D.Y., Rosenthal O.E., and Estabrook R.W. Function of cytochrome P-450 of microsomes. Fed Proc 24 (1965) 1181-1189
50. Habig W.H., Pabst M.J., Jakoby W.B., and Glutathione S.-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249 (1974) 7130-7139
51. Dehnen W., Tomingas R., and Roos J. A modified method for the assay benzo[a]pyrene hydroxulase. Anal Biochem 53 (1973) 373-383
52. Lubet R.A., Mayer R.T., Cameron J.W., Nims R.W., Burke M.D., Wolff T., et al. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome (s) P-450 by Phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys 238 (1985) 43-48
53. Rose P.G. Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer. Sem Oncol Nursing 19 Suppl. 2 (2003) 25-35
54. Potten C.S., and Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 110 (1990) 1001-1020
55. Morris J.A. The kinetics of epithelial cell generation: its relevance to cancer and aging. J Theor Biol 199 (1999) 281-299
56. Britten R.A., Evans A.J., and Allalunis-Turner M.J. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 34 (1996) 367-374
57. Lipsztein R., Kredentser D., Dottino P., Goodman H.M., Dalton J.F., Bloomer W.D., et al. Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am J Clin Oncol 10 (1987) 527-530
58. Su C.G., Stein R.B., Lewis J.D., and Lichtenstein GR. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?. Digest Liver Dis 32 (2000) 518-531
59. Pectasides D., Pectasides E., and Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33 (2007) 177-190
60. Imyanitov E.N., and Moiseyenko V.M. Molecular-based choice of cancer therapy: realities and expectations. Clin Chim Acta 79 (2007) 1-13
61. Camitta B., Mahoney D., Leventhal B., Lauer S.J., Shuster J.J., Adair S., et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 12 (1994) 1383-1399
62. Mahoney Jr. D.H., Camitta B.M., Leventhal B.G., Shuster J.J., Civin C.J., Ganick D.J., et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukaemia. A Pediatric Oncology Group pilot study. Cancer 75 (1995) 2623-2631
63. Mahoney Jr. D.H., Shuster J., Nitschke R., Lauer S.J., Winick N., Steuber C.P., et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 16 (1998) 246-254
64. Hall P.M., Jenner M.A., and Ahern M.J. Hepatotoxicity in a rat model caused by orally administered methotrexate. Hepatology 14 (1991) 906-910
65. Mack D.R., Young R., Kaufman S.S., Ramey L., and Vanderhoof J.A. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 132 (1998) 830-835
66. Nygaard U., Toft N., and Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 75 (2004) 274-281
67. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 8 (1991) 301-312
68. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 (1999) 2001-2008
69. Peeters M., Koren G., Jakubovicz D., and Zipursky A. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther 43 (1988) 228-232
70. Mantdakis E., Smith A.K., Hynan L., Winik N.J., and Kamen B.A. Methotrexate polyglutamation may lack prognostic significance in children with B cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate. J Pediatr Hematol Oncol 24 (2002) 636-642
71. Cece R., Cazzaniga S., Morelli D., Sfondrini L., Bignotto M., Ménard S., et al. Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab Invest 75 (1996) 601-609
72. Goldberg M.T., Tackaberry L.E., Hardy M.H., and Noseworthy J.H. Nuclear aberrations in hair follicle cells of patients receiving cyclophosphamide: a possible in vivo assay for human exposure to genotoxic agents. Arch Toxicol 64 (1990) 116-121
73. Paus R., Handjiski B., Eichmuller S., and Czarnetzki B.M. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol 144 (1994) 719-734
74. Lindner G., Botchkarev V.A., Botchkareva N.V., Ling G., van der Veen C., and Paus R. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol 151 (1997) 1601-1617